Sign in to continue:

Friday, February 13th, 2026

Wilmar International Ltd: Bullish Reversal Signals Strong Upside Potential

Date: September 30, 2024
Broker: CGS International Securities

Company Overview

Wilmar International Ltd operates as a food processing company. The company is involved in a wide range of services including oil palm cultivation, edible oil refining, crushing, and grain processing. Wilmar also offers sugar, flour, and rice products, serving customers worldwide.

Technical Analysis

Wilmar’s stock has recently shown a strong bullish reversal, suggesting a potential upside. The daily timeframe chart indicates a reversal at the bottom of a corrective wave, hinting that the stock may continue moving upward.

Key Price Levels:

  • Entry Prices: 3.36, 3.20, 3.00
  • Support Levels:
    • Support 1: 3.20
    • Support 2: 2.94
  • Stop Loss: 2.88
  • Resistance Levels:
    • Resistance 1: 3.42
    • Resistance 2: 2.94
  • Target Prices:
    • Target 1: 3.64
    • Target 2: 4.20
    • Target 3: 4.61
    • Target 4: 5.00

Technical Indicators

  • Rate of Change: The short-term rate of change is rising sharply above the zero line, confirming the momentum.
  • Directional Movement Index (DMI): Both ADX and DM+ are moving up together, indicating a resurgence in bullish strength.
  • Stochastic Oscillator: The mid-term stochastic oscillator has confirmed an oversold crossover, suggesting that prices are likely to rise.
  • MACD: The long-term MACD histogram is positive, supporting a bullish outlook.
  • Volume: There has been a spike in volume above the 20-period average, adding further confirmation of buying interest.

Trend Outlook

Wilmar has been supported by an uptrend line for the past nine years, particularly in the weekly chart. This suggests that the corrective wave has ended, and the stock could experience further upward momentum.

Analyst Recommendation

Based on the current analysis, traders are advised to consider buying at HK$3.37 or accumulating on pullbacks at HK$3.20 or HK$3.00. A stop loss is recommended at 2.90, with potential for a short-term target of HK$3.64 and a long-term target of HK$5.00.

Traders are encouraged to shift their stop loss to break-even once the stock reaches the first target price of 3.64.

Analyst: Chua Wei Ren, CMT

Hong Leong Bank 3QFY25 Results: Earnings Miss, Target Price Lowered but BUY Maintained – Maybank IBG Analysis

Broker: Maybank Investment Bank Berhad Date of Report: May 29, 2025 Hong Leong Bank’s 3QFY25 Results: Navigating Earnings Pressure and Strategic Growth Executive Summary: Hong Leong Bank’s Earnings Dip but Resilience Remains Hong Leong...

text Download Copy code 1SEO title: SATS Ltd (SATS SP): Embedded Resilience & FY26F Outlook | CGS International Report 2 3Here’s a summary of the SATS Ltd (SATS SP) analysis from the CGS International report: 4 5* **Recommendation:** The report reiterates an “Add” rating for SATS Ltd with a higher target price (TP) of S\$3.60 [[1]]. 6* **Financial Performance:** 4QFY3/25 net profit was S\$38.7m, slightly ahead of estimates. Revenue growth remained consistent. SATS’s cargo tonnage has outpaced global cargo demand, indicating market share gains [[1]]. 7* **FY26F Outlook:** SATS’s growing market share is expected to support earnings growth in FY26F, even with potential trade tensions. Cargo volumes are expected to grow due to market share gains, offsetting potential softening cargo demand in the latter half of FY26F [[1]]. 8* **Earnings Estimates:** FY26F-27F EPS estimates are lifted by 7.9-8.5%, and FY28F estimates are introduced, implying a 3-year earnings CAGR of 15.0% [[1]]. 9* **Valuation:** The TP of S\$3.60 implies 17.3x FY27F P/E, similar to its pre-Covid-19 mean [[2]]. 10* **Key Risks:** Margin compression from weaker operating leverage due to softening cargo volumes and a decline in the aviation travel industry due to an economic downturn [[1]]. 11* **ESG:** SATS maintains a B- ESG combined score by LSEG, with a slight improvement in its Environmental pillar score [[5]]. 12* **Financial Summary:** Revenue, Operating EBITDA, and Net Profit are projected to increase through Mar-28F. Core EPS is also expected to grow [[1]]

CGS International May 26, 2025 SATS Ltd: Embedded Resilience to Tide Through FY26F – Market Share Gains Offset Global Cargo Weakness SATS Ltd: Overview of 4QFY3/25 Performance SATS Ltd reported a 4QFY3/25 net profit...

Innovent Biologics: Pharma Giant in the Making with Strong Growth Prospects

Company Highlights: Innovent Biologics is evolving from a biotech company to a major pharmaceutical player in China, driven by its diverse drug pipeline. Key drugs such as Sintilimab, the company’s leading anti-PD-1 antibody, and...